Cargando…
P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
Autores principales: | Aranda Orgilles, B., Chion-Sotinel, I., Grudman, S., Mumford, B., Dixon, C., Duchateau, P., Galetto, R., Gouble, A., Poirot, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429281/ http://dx.doi.org/10.1097/01.HS9.0000848540.36064.91 |
Ejemplares similares
-
Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023) -
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
por: Jo, Sumin, et al.
Publicado: (2022) -
Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013) -
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
por: Dupouy, Sandra, et al.
Publicado: (2022) -
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
por: Derippe, Thibaud, et al.
Publicado: (2022)